Trade Supernus Pharmaceuticals Inc - SUPN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 37.82 |
| Open | 37.66 |
| 1-Year Change | 32.61% |
| Day's Range | 37.23 - 37.69 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 37.68 | -0.15 | -0.40% | 37.83 | 37.83 | 37.19 |
| Jan 16, 2025 | 37.82 | 0.18 | 0.48% | 37.64 | 38.54 | 37.64 |
| Jan 15, 2025 | 38.20 | 0.93 | 2.50% | 37.27 | 38.35 | 37.27 |
| Jan 14, 2025 | 37.77 | 0.50 | 1.34% | 37.27 | 37.84 | 37.04 |
| Jan 13, 2025 | 37.52 | 0.38 | 1.02% | 37.14 | 37.97 | 36.51 |
| Jan 10, 2025 | 37.41 | 0.42 | 1.14% | 36.99 | 37.61 | 36.70 |
| Jan 8, 2025 | 37.95 | 1.06 | 2.87% | 36.89 | 38.19 | 36.50 |
| Jan 7, 2025 | 37.37 | 0.92 | 2.52% | 36.45 | 37.41 | 36.45 |
| Jan 6, 2025 | 36.94 | -0.22 | -0.59% | 37.16 | 38.00 | 36.72 |
| Jan 3, 2025 | 36.76 | 0.43 | 1.18% | 36.33 | 36.85 | 36.24 |
| Jan 2, 2025 | 36.37 | 0.16 | 0.44% | 36.21 | 36.76 | 35.74 |
| Dec 31, 2024 | 36.10 | 0.18 | 0.50% | 35.92 | 36.74 | 35.62 |
| Dec 30, 2024 | 36.83 | 0.28 | 0.77% | 36.55 | 37.19 | 35.88 |
| Dec 27, 2024 | 37.12 | 1.82 | 5.16% | 35.30 | 37.25 | 35.01 |
| Dec 26, 2024 | 36.17 | 0.86 | 2.44% | 35.31 | 36.25 | 35.16 |
| Dec 24, 2024 | 35.48 | 0.78 | 2.25% | 34.70 | 35.54 | 34.70 |
| Dec 23, 2024 | 35.51 | 0.77 | 2.22% | 34.74 | 35.55 | 34.46 |
| Dec 20, 2024 | 35.37 | 0.02 | 0.06% | 35.35 | 36.14 | 34.13 |
| Dec 19, 2024 | 35.70 | 0.66 | 1.88% | 35.04 | 35.71 | 34.83 |
| Dec 18, 2024 | 35.31 | -0.86 | -2.38% | 36.17 | 36.49 | 35.04 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Supernus Company profile
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Supernus Pharmaceuticals Inc revenues increased 12% to $420.7M. Net income decreased 47% to $51M. Revenues reflect Net product sales- Trokendi XR segment increase of 34% to $231.5M, Net product sales-APOKYN segment increase of 70% to $73.3M. Net income was offset by Selling/General/Admin. Expense increase of 47% to $131.4M (expense), Advertising Expense increase of 58% to $59.7M (expense).
Equity composition
Common Stock $0.001 Par, 5/12, 62M auth., 23,912,319 issd. Insiders own approx. 6.73%. IPO:TBA
| Industry: | Proprietary & Advanced Pharmaceuticals |
9715 Key West Avenue
ROCKVILLE
MARYLAND 20850
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com